American Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:June 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs
American Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer Post author:andrewkaretas Post published:June 18, 2020 Post category:DLL3/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer
Positive Progress in AlloCAR T™:The Revolution in Cell Therapy is on the Horizon Post author:andrewkaretas Post published:May 29, 2020 Post category:Perspectives Continue ReadingPositive Progress in AlloCAR T™:The Revolution in Cell Therapy is on the Horizon
American Society of Gene and Cell Therapy (ASGCT) May 2020 – TurboCAR™ T Cells: CAR T Cells with Constitutive, Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:May 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingAmerican Society of Gene and Cell Therapy (ASGCT) May 2020 – TurboCAR™ T Cells: CAR T Cells with Constitutive, Programmable Cytokine Signaling Outputs
American Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study Post author:andrewkaretas Post published:May 1, 2020 Post category:CD19/Scientific Publications Continue ReadingAmerican Society of Clinical Oncology (ASCO) May 2020 – First-in-Human Data of ALLO-501 and ALLO-647 in Relapsed/Refractory Large B-cell or Follicular Lymphoma (R/R LBCL/FL): ALPHA Study
Toward “Off-the-Shelf” Allogeneic CAR T Cells Post author:andrewkaretas Post published:April 18, 2020 Post category:PLATFORM/Scientific Publications Continue ReadingToward “Off-the-Shelf” Allogeneic CAR T Cells
American Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia Post author:andrewkaretas Post published:December 18, 2019 Post category:FLT3/Scientific Publications Continue ReadingAmerican Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia
American Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells Post author:andrewkaretas Post published:December 18, 2019 Post category:BCMA/Scientific Publications Continue ReadingAmerican Society of Hematology (ASH) Dec. 2019 – Allogeneic Anti-BCMA CAR T Cells Show Tumor Specific Killing Against Primary Multiple Myeloma Cells
American Association for Cancer Research (AACR) April 2019 – AlloCAR T™ Targeting CD70 For RCC Post author:andrewkaretas Post published:April 18, 2019 Post category:CD70/Scientific Publications Continue ReadingAmerican Association for Cancer Research (AACR) April 2019 – AlloCAR T™ Targeting CD70 For RCC
Five First-year Milestones Bringing Allogene Closer to its Goal of Revolutionizing Cancer Treatment Post author:andrewkaretas Post published:April 5, 2019 Post category:Perspectives Continue ReadingFive First-year Milestones Bringing Allogene Closer to its Goal of Revolutionizing Cancer Treatment
